$226M in cash, cash equivalents, restricted cash and short-term investments as of June 30, 2025, expected to fund operations for over two years before accounting for anticipated ZEVASKYN revenue beginning in 3Q 2025 and projected profitability in 1H 2026
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics announces employee inducement grants
- AscellaHealth highlights value of HUB partnership with Abeona Therapeutics
- Abeona Therapeutics Amends Loan Agreement with Avenue
- Abeona Therapeutics’ Gene Therapy Trial for MPS IIIA: A Promising Update
- Abeona announces ZEVASKYN available at new Qualified Treatment Center